Langiprav (Pravastatin Sodium)

Pravastatin works by inhibiting the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. This inhibition lowers intracellular cholesterol, leading to up‑regulation of LDL receptors and increased removal of LDL‑cholesterol from the bloodstream.

The appropriate dose of Langiprav is determined by the prescribing clinician based on the patient’s cholesterol levels, overall cardiovascular risk, age, renal function and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Statins, including pravastatin, are generally contraindicated during pregnancy because cholesterol synthesis is important for fetal development. Use while breastfeeding is also not recommended unless the benefits outweigh potential risks, and this decision should be made by a qualified healthcare professional.

To order Langiprav, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pravastatin is considered a hydrophilic statin with a lower potential for drug‑drug interactions compared with lipophilic agents such as simvastatin. It has a modest potency but a favorable safety profile, especially in patients who require fewer metabolic interactions.

Langiprav tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Langiprav is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions given by the healthcare provider.

The most serious adverse events include rhabdomyolysis, a rare but severe muscle breakdown that can lead to kidney injury, and significant liver enzyme elevations indicating possible hepatotoxicity. Patients should report unexplained muscle pain, weakness or dark urine promptly.

Langiprav should be avoided in patients with active liver disease, unexplained persistent elevations of transaminases, known hypersensitivity to pravastatin or any component of the formulation, and in women who are pregnant or planning pregnancy.